Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

SBTX

Silverback Therapeutics (SBTX)

Silverback Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SBTX
DatumZeitQuelleÜberschriftSymbolFirma
28/06/202322h32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
15/05/202315h08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SBTXSilverback Therapeutics Inc
15/05/202315h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
09/05/202315h13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
08/05/202322h35Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:SBTXSilverback Therapeutics Inc
01/05/202322h42Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:SBTXSilverback Therapeutics Inc
01/05/202322h31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SBTXSilverback Therapeutics Inc
23/03/202321h14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SBTXSilverback Therapeutics Inc
23/03/202321h12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
13/03/202314h29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
23/02/202322h01GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle InjectorsNASDAQ:SBTXSilverback Therapeutics Inc
22/02/202322h12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
22/02/202322h05GlobeNewswire Inc.ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
13/02/202322h33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SBTXSilverback Therapeutics Inc
09/02/202312h30GlobeNewswire Inc.ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023NASDAQ:SBTXSilverback Therapeutics Inc
17/01/202323h07Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:SBTXSilverback Therapeutics Inc
17/01/202322h31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SBTXSilverback Therapeutics Inc
05/01/202323h02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
05/01/202323h02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
05/01/202323h02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
05/01/202323h01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
05/01/202323h01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
05/01/202323h01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
05/01/202323h01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
09/12/202223h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
06/12/202223h08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
01/12/202222h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
30/11/202222h24Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SBTXSilverback Therapeutics Inc
21/11/202222h08Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:SBTXSilverback Therapeutics Inc
18/11/202223h07Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:SBTXSilverback Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SBTX